# A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

> **NCT06612775** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhimeng Biopharma, Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Focal Epilepsy

## Interventions

- **DRUG:** Test drug CB03-154 5mg group
- **DRUG:** Test drug CB03-154 10mg group
- **DRUG:** Test drug CB03-154 20mg group
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT06612775
- **Lead sponsor:** Shanghai Zhimeng Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09
- **Primary completion:** 2026-08
- **Final completion:** 2026-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612775, "A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06612775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*